Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidence-based review with good practice points. EALSC Working Group

Amyotrophic Lateral Sclerosis

Volumn 8, Issue 4, 2007, Pages 195-213

  Andersen, Peter Munch ^a   Borasio, Gian Domenico ^b   Dengler, Reinhard ^c   Hardiman, Orla ^d   Kollewe, Katja ^c   Leigh, Peter Nigel ^e   Pradat, Pierre Francois ^f   Silani, Vincenzo ^g   Tomik, Barbara ^h  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d BEAUMONT HOSPITAL   (Ireland)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITY OF MILAN   (Italy)

^h JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

ALS SLA MND; Breaking the diagnosis; Bronchial secretions; Diagnosis; DNA testing; Drooling; EALSC; Nutrition; Palliative care; Symptomatic treatment; Terminal care; Ventilation

Indexed keywords

ACETYLCYSTEINE; AMITRIPTYLINE; ARUNDIC ACID; ATROPINE; BACLOFEN; CELECOXIB; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; CYCLOSPORIN; DANTROLENE; DEXTROMETHORPHAN; DIAZEPAM; GABAPENTIN; INDINAVIR; MEMANTINE; NIMODIPINE; NORPHENAZONE; OXANDROLONE; PENTOXIFYLLINE; QUINIDINE; QUININE SULFATE; RILUZOLE; SCOPOLAMINE; TAMOXIFEN; THALIDOMIDE; TIZANIDINE; TOPIRAMATE; UNINDEXED DRUG; VERAPAMIL; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONSULTATION; COUGHING; DEPRESSION; DRUG COST; EARLY DIAGNOSIS; EMOTIONAL DISORDER; ENTERIC FEEDING; EVIDENCE BASED PRACTICE; GENETIC ANALYSIS; GENETIC COUNSELING; GOOD CLINICAL PRACTICE; HEALTH CARE ORGANIZATION; HUMAN; HYPERSALIVATION; INSOMNIA; INTERPERSONAL COMMUNICATION; MANAGED CARE; MEDICAL SPECIALIST; MUSCLE CRAMP; NEUROLOGY; PALLIATIVE THERAPY; PATIENT AUTONOMY; PATIENT CARE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHYSIOTHERAPY; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RELATIVE; REVIEW; SPASTICITY; SUPPORT GROUP; SURGICAL RISK; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VITAL CAPACITY;

AMYOTROPHIC LATERAL SCLEROSIS; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 34547562663     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/17482960701262376     Document Type: Review

References (133)

1. Abrahams, S., Goldstein, L. H., Kew, J. J., Brooks, D. J., Lloyd, C. M. and Frith, C. D. (1996) Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain, 119, pp. 2105-2120.
2. Forsgren, L., Almay, B. G., Holmgren, G. and Wall, S. (1983) Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand, 68, pp. 20-29.
3. Haverkamp, L. J., Appel, V. and Appel, S. H. (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain, 118, pp. 707-719.
4. Bobowick, A. R. and Brody, J. A. (1973) Epidemiology of motor neuron diseases. N Engl J Med, 288, pp. 1047-1055.
5. Ince, P. G., Lowe, J. and Shaw, P. J. (1998) Amyotrophic lateral sclerosis: Current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol, 24, pp. 104-117.
6. Brugman, F., Wokke, J. H., de Jong, J. M. Vianney, Franssen, H., Faber, C. G. and Berg, L. H. van den (2005) Primary lateral sclerosis as a phenotypic manifestation of familial ALS. Neurology, 64, pp. 1778-1779.
7. Andersen, P. M., Borasio, G. D., Dengler, R., Hardiman, O., Kollewe, K. and Leigh, P. N. (2005) EFNS Task Force on Management of Amyotrophic Lateral Sclerosis. Guidelines for diagnosing and clinical care of patients and relatives. An evidence-based review with Good Practice Points. Eur J Neurol, 12, pp. 921-938.
8. Brainin, M., Barnes, M., Baron, J. C., Gilhus, N. E., Hughes, R. and Selmaj, K. (2004) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces: Revised recommendations 2004. Eur J Neurol, 11, pp. 577-581.
9. Li, T. M., Day, S. J., Alberman, E. and Swash, M. (1986) Differential diagnosis of motor neuron disease from other neurological conditions. Lancet, 2, pp. 731-733.
10. Wilbourn, A. J. (1998) Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: The Lambert and the El Escorial criteria. J Neurol Sci, 160, p. S25.
11. Meininger, V. (1999) Getting the diagnosis right: Beyond El Escorial. J Neurol, 246, pp. 10-15.
12. Chio, A. (1999) Survey: An international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol, 246, pp. 1-5.
13. Chio, A. (2000) Update on ISI survey: Europe, North America and South America. Amyotroph Lateral Scler Other Motor Neuron Disord, p. S9.
14. Bromberg, M. (1999) Accelerating the diagnosis of amyotrophic lateral sclerosis. The Neurologist, 5, pp. 63-74.
15. Aggarwal, A. and Nicholson, G. (2002) Detection of preclinical motor neuron loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry, 73, pp. 199-201.
16. Dengler, R. and Tröger, M. (2001) Impact of riluzole on the relationship between patient and physician. J Neurol, 244, p. S30.
17. Lima, A., Evangelista, T. and de Carvalho, M. (2003) Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyography and Clinical Neurophysiology, 43, pp. 189-192.
18. Evangelista, T., Carvalho, M., Conceicao, I., Pinto, A., de Lurdes, M. and Luis, M. L. (1996) Motor neuropathies mimicking amyotrophic lateral sclerosis/motor neuron disease. J Neurol Sci, 139, pp. 95-98.
19. Traynor, B. J., Codd, M. B., Corr, B., Forde, C., Frost, E. and Hardiman, O. (2000) Amyotrophic lateral sclerosis mimic syndromes. Arch Neurol, 57, pp. 109-113.
20. Belsh, J. M. and Schiffman, P. L. (1996) The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and it repercussions. J Neurol Sci, 139, pp. 110-116.
21. Davenport, R. J., Swingler, R. J., Chancellor, A. M. and Warlow, C. P. (1996) Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry, 60, pp. 147-151.
22. Brooks, B. R. (1999) Earlier is better: The benefits of early diagnosis. Neurology, 53, p. S53.
23. Brooks, B. R., Miller, R. G. and Swash, M. (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord, 1, pp. 293-299.
24. Ross, M. A., Miller, R. G., Berchert, L., Parry, G., Barohn, R. J. and Armon, C. (1998) Towards earlier diagnosis of ALS. Revised criteria. Neurology, 50, pp. 768-772.
25. Leigh, P. N., Abrahams, S., Al-Chalabi, A., Ampong, M. A., Goldstein, L. H., Johnson, J. and King's MND Care and Research Team (2003) The management of motor neuron disease. J Neurol Neurosurg Psychiatry, 70, pp. 32-47.
26. Lind, S. E., Good, M. D., Seidel, S., Csordas, T. and Good, B. J. (1989) Telling the diagnosis in cancer. J Clin Oncol, 7, pp. 583-589.
27. Damian, D. and Tattersall, M. H. N. (1991) Letters to patients: improving communication in cancer care. Lancet, 338, pp. 923-925.
28. Doyle, D. (1996) Breaking bad news. J Royal Soc Med, 89, pp. 590-591.
29. Davies, E. and Hopkins, A. (1997) Good practice in the management of adults with malignant cerebral glioma: Clinical guidelines. Working Group. Br J Neurosurg, 11, pp. 318-330.
30. Miller, R. G., Rosenberg, J. A., Gelinas, D. F., Mitsumoto, H., Newman, D. and Sufit, R. (1999) Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology, 52, pp. 1311-1323.
31. Borasio, G. D., Sloan, R. and Pongratz, D. E. (1998) Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci, 160, p. S127.
32. McCluskey, L., Casarett, D. and Siderowf, A. (2004) Breaking the news: A survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord, 5, pp. 131-135.
33. Borasio, G. D., Shaw, P. J., Hardiman, O., Ludolph, A. C., Luis, M. L. Sales, Silani, V. and for the European ALS Study Group (2001) Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord, 2, pp. 159-164.
34. Ackerman, G. M. and Oliver, D. (1997) Psychosocial support in an outpatient clinic. Palliat Med, 11, pp. 167-168.
35. Chio, A., Silani, V. and Italian ALS Study Group (2001) ALS care in Italy: A nationwide study in neurological centres. J Neurol Sci, 191, pp. 145-150.
36. Howard, R. S. and Orrell, R. W. (2002) Management of motor neuron disease. Postgrad Med J, 78, pp. 736-741.
37. Traynor, B. J., Alexander, M., Corr, B., Frost, E. and Hardiman, O. (2003) Effects of a multidisciplinary ALS clinic on survival. J Neurol Neurosurg Psychiatry, 74, pp. 1258-1261.
38. Lee, J. R. J., Annegers, J. F. and Appel, S. (1995) Prognosis of ALS and the effects of referral selection. J Neurol Sci, 132, pp. 207-215.
39. Chio, A., Mora, G., Balzarino, C. and Mutani, R. (2004) Interdisciplinary ALS Centres: Effect of survival and use of health services in a population-based survey. Neurology, 62, p. S23.003.
40. Bensimon, G., Lacomblez, L. and Meininger, V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med, 330, pp. 585-591.
41. Lacomblez, L., Bensimon, G., Leigh, P. N., Guillet, P. and Meininger, V. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet, 347, pp. 1425-1431.
42. Miller, R. G., Mitchell, J. D., Lyon, M. and Moore, D. H. (2002) Riluzole for amyotrophic lateral sclerosis (ALS/motor neuron disease (MND). Cochrane Database Syst Rev, 2, p. CD001447.
43. Brooks, B. R., Belden, D. S., Roelke, K., Parnell, J., Peper, S. and Houdek, A. (2001) Survival in non-riluzole treated ALS patients is identical before and since 1996: A clinic-based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Disord, 2, pp. 60-61.
44. Turner, M. R., Bakker, M., Sham, P., Shaw, C. E., Leigh, P. N. and Al-Chalabi, A. (2002) Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord, 3, pp. 15-21.
45. Traynor, B. J., Alexander, M., Corr, B., Frost, E. and Hardiman, O. (2003) An outcome study of riluzole in amyotrophic lateral sclerosis: A population-based study in Ireland, 1996-2000. J Neurol, 250, pp. 473-479.
46. Andersen, P. M., Sims, K. B., Xin, W. W., Kiely, R., O'Neill, G. and Ravits, J. (2003) Sixteen novel mutations in the gene encoding Cu/ Zn-superoxide dismutase in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord, 2, pp. 62-73.
47. Silani, V., Cova, L., Corbo, M., Ciammola, A. and Polli, E. (2004) Stem-cell therapy for amyotrophic lateral sclerosis. Lancet, 364, pp. 200-202.
48. Czaplinski, A., Schweikert, K., Strobel, W., Steck, A. J. and Weber, M. (2006) Symtomatische Therapie der amyotrophen lateralsklerose (ALS). Praxis, 95, pp. 263-271.
49. Forshew, D. A. and Bromberg, M. B. (2003) A survey of clinicans' practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord, 4, pp. 258-263.
50. Hyson, H. C., Johnson, A. M. and Jog, M. S. (2002) Sublingual atropine for sialorrhoea secondary to Parkinsonism: A pilot study. Mov Disord, 17, pp. 1318-1320.
51. Mier, R. J., Bachrach, S. J., Lakin, R. C., Barker, T., Childs, J. and Moran, M. (2000) Treatment of sialorrhoea with glycopyrrolate: A double-blind, dose-ranging study. Arch Pediatr Adolesc Med, 154, pp. 1214-1218.
52. Talmi, Y. P., Finkelstein, Y. and Zohar, Y. (1989) Reduction of salivary flow in amyotrophic lateral sclerosis with Scopoderm TTS. Head Neck, 11, p. 565.
53. Talmi, Y. P., Finkelstein, Y. and Zohar, Y. (1990) Reduction of salivary flow with transdermal scopolamine: A four-year experience. Otolaryngol Head Neck Surg, 103, pp. 615-618.
54. Camp-Bruno, J. A., Winsberg, B. F., Green-Parsons, A. R. and Abrams, J. P. (1989) Efficacy of benztropine therapy for drooling. Dev Med Child Neurol, 31, pp. 309-319.
55. Tan, E-K. (2006) Botulinum toxin treatment of sialorrhoea: Comparing different therapeutic preparations. Eur J Neurol, 13, pp. 60-64.
56. Giess, R., Naumann, M., Werner, E., Riemann, R., Beck, M. and Puls, I. (2000) Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 69, pp. 121-123.
57. Porta, M., Gamba, M., Bertacchi, G. and Vaj, P. (2001) Treatment of sialorrhoea with ultrasound guided botulinum toxin A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry, 70, pp. 538-540.
58. Dogu, O., Apaydin, D., Sevim, S., Talas, D. U. and Aral, M. (2004) Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg, 106, pp. 93-96.
59. Tan, E-K., Lo, Y. L., Seah, A. and Auchus, A. P. (2001) Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci, 190, pp. 95-97.
60. Winterholler, M. G., Erbguth, F. J., Wolf, S. and Kat, S. (2001) Botulinum toxin for the treatment of sialorrhoea in ALS: Serious side-effects of a transductal approach. J Neurol Neurosurg Psychiatry, 70, pp. 417-418.
61. Andersen, P. M., Gronberg, H., Frankzen, L. and Funegard, U. (2001) External radiation of the parotid glands significantly reduces drooling in patients with motor neuron disease with bulbar paresis. J Neurol Sci, 191, pp. 111-114.
62. Harriman, M., Morrison, M., Hay, J., Revonta, M., Eisen, A. and Lentle, B. (2001) Use of radiotherapy for control of sialorrhoea in patients with amyotrophic lateral sclerosis. J Otolaryngol, 30, pp. 242-245.
63. Stalpers, L. J. and Moser, E. C. (2002) Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology, 58, p. 1308.
64. Burton, M. J. (1991) The surgical management of drooling. Dev Med Child Neurol, 33, pp. 1110-1116.
65. Hockstein, N. G., Samadi, D. S., Gendron, K. and Handler, S. D. (2004) Sialorrhoea: A management challenge. Am Fam Physician, 69, pp. 2628-2634.
66. Janzen, V. D., Rae, R. E. and Hudson, A. J. (1988) Otolaryngologic manifestations of ALS. J Otolaryngology, 17, pp. 41-42.
67. Newall, A. R., Orser, R. and Hunt, M. (1996) The control of oral secretions in bulbar ALS/MND. J Neurol Sci, 139, pp. 43-44.
68. Hanayama, K., Ishikawa, Y. and Bach, J. R. (1997) Amyotrophic lateral sclerosis: Successful treatment of mucous plugging by mechanical insufflation-exsufflation. Am J Phys Med Rehabil, 76, pp. 338-339.
69. Sancho, J., Servera, E., Diaz, J. and Marin, J. (2004) Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest, 125, pp. 1400-1405.
70. Gallagher, J. P. (1989) Pathological laughter and crying in ALS: A search for their origin. Acta Neurol Scand, 80, pp. 114-117.
71. Brooks, B. R., Thisted, R. A., Appel, S. H., Bradley, W. G., Olney, R. K. and Berg, J. E. (2004) Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. The AVP-923 ALS Study Group. Neurology, 63, pp. 1364-1370.
72. Iannaccone, S. and Ferini-Strambi, L. (1996) Pharmacological treatment of emotional lability. Clin Neuropharmacol, 19, pp. 532-535.
73. Schiffer, R. B., Herndon, R. M. and Rudick, R. A. (1985) Treatment of pathological laughing and weeping with amitriptyline. N Engl J Med, 312, pp. 1480-1482.
74. Andersen, G., Vestergaard, K. and Riis, J. O. (1993) Citalopram for post-stroke pathological crying. Lancet, 342, pp. 837-839.
75. Poeck, K. (1996) Pathologisches lachen und weinen bei bulber amyotrophischer lateralsklerose. Deutsche Med Wochenschr, 94, pp. 310-314.
76. Connolly, P. S., Shirley, E. A., Wasson, J. H. and Nierenberg, D. W. (1992) Treatment of nocturnal leg cramps. A crossover trial of quinine vs. vitamin E. Arch Intern Med, 152, pp. 1877-1880.
77. Diener, H. C., Dethlefsen, U., Dethlefsen-Gruber, S. and Verbeek, P. (2002) Effectiveness of quinine in treating muscle cramps: A double-blind, placebo-controlled, parallel-group, multicentre trial. Int J Clin Pract, 56, pp. 243-246.
78. Drory, V. E., Goltsman, E., Reznik, J. G., Mosek, A. and Korczyn, A. D. (2001) The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci, 191, pp. 133-137.
79. Kesiktas, N., Paker, N., Erdogan, N., Gulsen, G., Bicki, D. and Yilmaz, H. (2004) The use of hydrotherapy for the management of spasticity. Neurorehabil Neural Repair, 18, pp. 268-273.
80. Santos, M. T. dos and de Oliveira, L. M. (2004) Use of cryotherapy to enhance mouth opening in patients with cerebral palsy. Spec Care Dentist, 24, pp. 232-234.
81. FH, J. r. Norris, Ks., U., Sachais, B. and Carey, M. (1979) Trial of baclofen in amyotrophic lateral sclerosis. Arch Neurol, 36, pp. 715-716.
82. Marquardt, G. and Seifert, V. (2002) Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 72, pp. 275-276.
83. Rocha, J. A., Reis, C., Simoes, F., Fonseca, J. and Ribeiro, J. Mendes (2005) Diagnostic investigation and multidisciplinary management in motor neuron disease. J Neurol, 252, pp. 1435-1447.
84. Winterholler, M. G., Heckmann, J. G., Hecht, M. and Erbguth, F. J. (2002) Recurrent trismus and stridor in an ALS patient: Successful treatment with botulinum toxin. Neurology, 58, pp. 502-503.
85. Dengler, R. (1999) Current treatment pathways in ALS: A European perspective. Neurology, 53, p. S4.
86. Miller, R. G. (2001) Examining the evidence about treatment in ALS/MND. Amyotroph Lateral Scler Other Motor Neuron Disord, 2, pp. 3-7.
87. Haberlandt, W. F. (1959) Genetic aspects of amyotrphic lateral sclerosis and progressive bulbar paralysis. Acta Genet Med Gemell, 8, pp. 369-373.
88. Murros, K. and Fogelholm, R. (1983) Amyotrophic lateral sclerosis in middle-Finland: An epidemiological study. Acta Neurol Scand, 67, pp. 41-47.
89. Thijs, V., Peeters, E., Theys, P., Matthijs, G. and Robberecht, W. (2000) Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg, 100, pp. 84-90.
90. Murray, T. J., Pride, S. and Haley, G. (1974) Motor neuron disease in Nova Scotia. Can Med Assoc J, 110, pp. 814-817.
91. Gunnarsson, L-G. and Palm, R. (1984) Motor neuron disease and heavy labour: An epidemiological survey of Värmland county, Sweden. Neuroepidemiology, 3, pp. 195-206.
92. Li, T-M., Alberman, E. and Swash, M. (1988) Comparison of sporadic and familial disease among 580 cases of motor neuron disease. J Neurol Neurosurg Psychiatry, 51, pp. 778-784.
93. Rosen, A. D. (1978) Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol, 35, pp. 638-642.
94. Giagheddu, M., Puggioni, G., Masala, C., Biancu, F., Pirari, G. and Piras, M. R. (1983) Epidemiological study of amyotrophic lateral sclerosis in Sardinia, Italy. Acta Neurol Scand, 68, pp. 394-404.
95. Højer-Pedersen, E., Christensen, P. B. and Jensen, N. B. (1989) Incidence and prevalence of motor neuron disease in two Danish counties. Neuroepidemiology, 8, pp. 151-159.
96. Fong, K. Y., Yu, Y. L., Chan, Y. W., Kay, R., Chan, J. and Yang, Z. (1996) Motor neuron disease in Hong Kong Chinese: Epidemiology and clinical picture. Neuroepidemiology, 15, pp. 239-245.
97. Jokelainen, M. (1977) Amyotrophic lateral sclerosis in Finland. II: Clinical characteristics. Acta Neurol Scand, 56, pp. 194-204.
98. Andersen, P. M., Forsgren, L., Binzer, M., Nilsson, P., Ala-Hurula, V. and Keranen, M. L. (1996) Autosomal recessive adult-onset ALS associated with homozygosity for Asp90Ala Cu/Zn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain, 119, pp. 1153-1172.
99. Corrado, L., D'Alfonso, S., Bergamaschi, L., Testa, L., Leone, M. and Nasuelli, N. (2006) SOD1 gene mutations in Italian patients with sporadic amyotrophic lateral sclerosis (ALS). Neuromuscul Disord, 16, pp. 800-804.
100. Jones, C. T., Swingler, R. J., Simpson, S. A. and Brock, D. J. (1995) Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet, 32, pp. 290-292.
101. Gellera, C. (2001) Genetics of ALS in Italian families. Amyotroph Lateral Scler Other Motor Neuron Disord, 2, p. S43.
102. Andersen, P. M., Nilsson, P., Keranen, M. L., Forsgren, L., Hagglund, J. and Karlsborg, M. (1997) Phenotypic heterogeneity in MND patients with Cu/Zn-superoxide dismutase mutations in Scandinavia. Brain, 10, pp. 1723-1737.
103. Shaw, C. E., Enayat, Z. E., Chioza, B. A., Al-Chalabi, A., Radunovic, A. and Powell, J. F. (1998) Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol, 43, pp. 390-394.
104. Jackson, M., Al-Chalabi, A., Enayat, Z. E., Chioza, B., Leigh, P. N. and Morrison, K. E. (1997) Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: Analysis of 155 cases and identification of a novel insertion mutation. Ann Neurol, 42, pp. 803-807.
105. Garcia-Redondo, A., Bustos, F., Seva, B. Juan Y., Hoyo, P. Del, Jimenez, S. and Campos, Y. (2002) Molecular analysis of the superoxide dismutase 1 gene in Spanish patients with sporadic or familial amyotrophic lateral sclerosis. Muscle Nerve, 26, pp. 274-278.
106. Battistini, S., Giannini, F., Greco, G., Bibbo, G., Ferrera, L. and Marini, V. (2005) SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicentre Italian study. J Neurol, 252, pp. 782-788.
107. Cudkowicz, M. E., McKenna-Yasek, D., Sapp, P. E., Chin, W., Geller, B. and Hayden, D. L. (1997) Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol, 41, pp. 210-221.
108. Boukaftane, Y., Khoris, J., Moulard, B., Salachas, F., Meininger, V. and Malafosse, A. (1998) Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci, 25, pp. 192-196.
109. Niemann, S., Joos, H., Meyer, T., Vielhaber, S., Reuner, U. and Gleichmann, M. (2004) Familial ALS in Germany: Origin of the R115G SOD1 mutation by a founder effect. J Neurol Neurosurg Psychiatry, 75, pp. 1186-1188.
110. Gasser, T., Dichgans, M., Finsterer, J., Hausmanowa-Petrusewicz, I., Jurkat-Rott, K. and Klopstock, T. (2001) EFNS task force on molecular diagnosis of neurological disorders. Part 1. Eur J Neurol, 8, pp. 299-314.
111. Lyall, R. A., Donaldson, N., Polkey, M. I., Leigh, P. N. and Moxham, J. (2001) Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain, 124, pp. 2000-2013.
112. Bourke, S. C. and Gibson, G. J. (2004) Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler Other Motor Neuron Disord, 5, pp. 67-71.
113. Annane, D., Chevrolet, J. C., Chevret, S. and Raphael, J. C. (2000) Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev, p. CD001941.
114. Bourke, S. C., Tomlinson, M., Williams, T. L., Bullock, R. E., Shaw, P. J. and Gibson, G. J. (2006) Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomized controlled trial. Lancet Neurol, 5, pp. 140-147.
115. Mustfa, N., Walsh, E., Bryant, V., Lyall, R. A., Addington-Hall, J. and Goldstein, L. H. (2006) The effect of non-invasive ventilation on ALS patients and their caregivers. Neurology, 66, pp. 1211-1217.
116. Cazzolli, P. A. and Oppenheimer, E. A. (1996) Home mechanical ventilation for amyotrophic lateral sclerosis: Nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci, 139, pp. 123-128.
117. Jennings, A. L., Davies, A. N., Higgins, J. P., Gibbs, J. S. and Broadley, K. E. (2002) A systematic rof the use of opioids in the management of dyspnoea. Thorax, 57, pp. 939-944.
118. Bruera, E., Sweeney, C., Willey, J., Palmer, J. L., Strasser, F. and Morice, R. C. (2003) A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnoea. Palliat Med, 17, pp. 659-663.
119. Desport, J. C., Preux, P. M., Truong, C. T., Courat, L., Vallat, J. M. and Couratier, P. (2000) Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord, 1, pp. 91-96.
120. Heffernan, C., Jenkinson, C., Holmes, T., Feder, G., Kupfer, R. and Leigh, P. N. (2004) Nutritional management in MND/ALS patients: An evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord, 5, pp. 72-83.
121. Mathus-Vliegen, L. M., Louwerse, L. S., Merkus, M. P., Tytgat, G. N. and de Jong, J. M. Vianney (1994) Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc, 40, pp. 463-469.
122. Shaw, A. S., Ampong, M. A., Rio, A., Al-Chalabi, A., Sellars, M. E. and Ellis, C. (2006) Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: A retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler, 7, pp. 16-21.
123. Chio, A., Galletti, R., Finocchiaro, C., Righi, D., Ruffino, M. A. and Calvo, A. (2004) Percutaneous radiologic gastrostomy: A safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry, 75, pp. 645-647.
124. Shaw, A. S., Ampong, M. A., Rio, A., McClure, J., Leigh, P. N. and Sidhu, P. S. (2004) Entristar skin-level gastrostomy tube: Primary placement with radiologic guidance in patients with amyotrophic lateral sclerosis. Radiology, 233, pp. 392-399.
125. Thornton, F. J., Fotheringham, T., Alexander, M., Hardiman, O., McGrath, F. P. and Lee, M. J. (2002) Amyotrophic lateral sclerosis: Enteral nutrition provision-endoscopic or radiologic gastrostomy?. Radiology, 224, pp. 713-717.
126. Scott, A. G. and Austin, H. E. (1994) Nasogastric feeding in the management of severe dysphagia in motor neuron disease. Palliat Med, 8, pp. 45-49.
127. Bak, T. H. and Hodges, J. R. (2004) The effects of motor neuron disease on language: Further evidence. Brain Lang, 89, pp. 354-361.
128. Cobble, M. (1998) Language impairment in motor neuron disease. J Neurol Sci, 160, p. S47.
129. Murphy, J. (2004) Communication strategies of people with ALS and their partners. Amyotroph Lateral Scler Other Motor Neuron Disord, 5, pp. 121-126.
130. Borasio, G. D., Voltz, R. and Miller, R. G. (2001) Palliative Care in Amyotrophic Lateral Sclerosis. Neurol Clin, 19, pp. 829-847.
131. Oliver, D., Borasio, G. D. and Walsh Eds, D. (2006) Palliative Care in Amyotrophic Lateral Sclerosis., Oxford University Press, Oxford
132. Mitsumoto, H., Bromberg, M., Johnston, W., Tandan, R., Byock, I. and Lyon, M. (2005) Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler, 6, pp. 145-154.
133. Sykes, N. and Thorns, A. (2003) The use of opioids and sedatives at the end of life. Lancet Oncology, 4, pp. 312-318.